Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colo-rectal Cancer
Metastatic Cancer

Interventions: Drug: Regorafenib
Drug: Cyclophosphamide
Drug: Capecitabine
Drug: Aspirin

First Posted Date: 2020-09-01

Last Posted Date: 2024-12-20

Lead Sponsor: Centre Hospitalier Universitaire de Besancon

Target Recruit Count: 49

Registration Number: NCT04534218

Locations: 🇫🇷
Hôpital Nord Franche-Comté, Montbéliard, France
🇫🇷
CHU de Besançon, Besançon, France
🇫🇷
Centre georges-François Leclerc, Dijon, France

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

Phase 3

Active, not recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: placebo
Drug: acalabrutinib
Drug: Prednisone
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Doxorubicin

First Posted Date: 2020-08-28

Last Posted Date: 2024-12-19

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 611

Registration Number: NCT04529772

Locations: 🇺🇦
Research Site, Zaporizhzhia, Ukraine

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Phase 3

Recruiting

Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Biological: Blinatumomab
Drug: Dasatinib
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Procedure: Multigated Acquisition Scan
Drug: Ponatinib Hydrochloride
Procedure: Echocardiography
Procedure: Electrocardiography
Drug: Prednisone
Procedure: Lumbar Puncture
Drug: Methotrexate
Drug: Mesna
Drug: Vincristine Sulfate

First Posted Date: 2020-08-28

Last Posted Date: 2025-01-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 348

Registration Number: NCT04530565

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States

and more 203 locations

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

Phase 1

Terminated

Conditions: Neoplasms

Interventions: Drug: GSK3845097
Drug: GSK3901961
Drug: GSK4427296
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2020-08-25

Last Posted Date: 2024-11-26

Lead Sponsor: Adaptimmune

Target Recruit Count: 12

Registration Number: NCT04526509

Locations: 🇸🇪
GSK Investigational Site, Stockholm, Sweden

ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: ME-401
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2020-08-18

Last Posted Date: 2023-12-20

Lead Sponsor: Deepa Jagadeesh

Target Recruit Count: 13

Registration Number: NCT04517435

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children

Phase 1

Recruiting

Conditions: Malignant Brain Neoplasm
Refractory Malignant Brain Neoplasm
Recurrent Malignant Brain Neoplasm

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes

First Posted Date: 2020-08-12

Last Posted Date: 2024-10-09

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 18

Registration Number: NCT04510051

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

Phase 2

Recruiting

Conditions: Diffuse Large B-Cell Lymphoma
High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements
High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements
Double Expressor Lymphoma
High-grade B-cell Lymphoma

Interventions: Drug: Prednisone
Drug: Prednisolone
Drug: Methylprednisolone
Biological: Rituximab
Drug: Polatuzumab Vedotin
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride

First Posted Date: 2020-07-21

Last Posted Date: 2024-03-20

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 49

Registration Number: NCT04479267

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

Haplo Peripheral Blood Sct In GVHD Prevention

Phase 1

Active, not recruiting

Conditions: GVHD
AML
ALL
MDS
MPN
CMML
Hodgkin Lymphoma
Non Hodgkin Lymphoma
Blood Stem Cell Transplant Failure
Graft Vs Host Disease

Interventions: Drug: FLUDARABINE
Drug: CYCLOPHOSPHAMIDE
Radiation: TBI
Drug: Melphalan
Drug: Sirolimus
Drug: Mycophenolate mofetil
Drug: RGI-2001

First Posted Date: 2020-07-16

Last Posted Date: 2024-03-07

Lead Sponsor: Zachariah Michael DeFilipp

Target Recruit Count: 25

Registration Number: NCT04473911

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

Phase 2

Recruiting

Conditions: Solid Tumor

Interventions: Drug: Sirolimus
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Celecoxib

First Posted Date: 2020-07-14

Last Posted Date: 2024-11-13

Lead Sponsor: Emory University

Target Recruit Count: 50

Registration Number: NCT04469530

Locations: 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Aflac Cancer & Blood Disorders Centers, Atlanta, Georgia, United States
🇺🇸
Texas Children's Cancer Center, Houston, Texas, United States

and more 2 locations

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Phase 2

Recruiting

Conditions: Triple Negative Breast Cancer
Biopsy-proven, Positive Lymph Node(s)
Hormone Receptor Positive (HR+), HER2-negative Breast Cancer

Interventions: Radiation: Radiation Therapy Boost
Drug: Pembrolizumab
Drug: Paclitaxel
Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Capecitabine

First Posted Date: 2020-06-23

Last Posted Date: 2024-03-19

Lead Sponsor: Laura M. Spring, MD

Target Recruit Count: 120

Registration Number: NCT04443348

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
University of North Carolina Medical Center, Chapel Hill, North Carolina, United States
🇺🇸
Johns Hopkins, Baltimore, Maryland, United States

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy